SAM
GYRE icon

Smartleaf Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Smartleaf Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41 Hold
6
– – ﹤0.01% 3445
2025
Q4 		$42 Buy
+6
New +$46 ﹤0.01% 3443

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Smartleaf Asset Management's GYRE Position: Q1 2026 in Review

Smartleaf Asset Management held its Gyre Therapeutics (GYRE) position steady in Q1 2026 at 6 shares worth $41. The position accounts for ﹤0.01% of the portfolio, ranked #3445.

Smartleaf Asset Management first reported a position in GYRE in Q4 2025 and has held it in 2 quarters since. The position peaked at $42 in Q4 2025. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Smartleaf Asset Management held 6 shares of Gyre Therapeutics worth $41 as of Q1 2026.
  • Smartleaf Asset Management left its Gyre Therapeutics share count unchanged in Q1 2026.
  • Gyre Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3445 holding.
  • Smartleaf Asset Management first reported a position in Gyre Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Smartleaf Asset Management's Gyre Therapeutics position peaked at $42 in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.